This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Mircera contains the active substance methoxy polyethylene glycol epoetin beta, and is a medicine that stimulates the growth of red blood cells. It is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients, and in pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA. It is given by subcutaneous or intravenous injections, using a pre-filled syringe.
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
M-PK-00001707
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
Please be aware that you are leaving this website.